BI 671800 clinical trials
Also written BI 671800.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses BI 671800 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BI 671800
- 6
Studies by the year they started
9 studies that test it; most in 2010 (8)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Often tested with
Tested in the same studies.
BI 67100 (1)
Studies
Open first, then newest update. How each study uses BI 671800 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- BI 671800 in Asthmatic Patients on Inhaled CorticosteroidsCompletedPhase 2Boehringer IngelheimNCT01103349Written as BI 671800
- BI 671800 ED in Steroid-naive Asthmatic PatientsCompletedPhase 2Boehringer IngelheimNCT01092143Written as BI 671800
- Bi 671800 in Asthmatic Patients on Inhaled CorticosteroidsCompletedPhase 2Boehringer IngelheimNCT01090024Written as BI 671800
- Relative Bioavailability of BI 671800 HEA in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02222233Written as BI 671800 HEA delayed release (enteric coated) tablet
- Relative Bioavailability of Different Formulations of BI 671800 in Healthy Male and Female VolunteersCompletedPhase 1Boehringer IngelheimNCT02221388Written as BI 671800 HEA, 200 mg tablets
- Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of SeasonCompletedPhase 2Boehringer IngelheimNCT01007721Written as BI 671800 ED 100 mg
- Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian VolunteersCompletedPhase 1Boehringer IngelheimNCT01216384Written as BI 671800
- Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.CompletedPhase 1Boehringer IngelheimNCT01215773Written as BI 671800
- A Phase I Trial to Investigate the Metabolism and Pharmacokinetics as Well as Safety and Tolerability of a Single Dose BI671800 HEA Administered as an Oral Solution of the Choline Salt in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT01205373Written as BI 671800